Production (Stage)
Bicycle Therapeutics plc
BCYC
$8.05
-$0.05-0.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -38.18% | 30.76% | 48.60% | 75.74% | 168.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -38.18% | 30.76% | 48.60% | 75.74% | 168.47% |
| Cost of Revenue | -49.57% | -64.17% | 25.65% | 37.26% | 62.44% |
| Gross Profit | 56.74% | 86.81% | -20.42% | -28.08% | -42.56% |
| SG&A Expenses | 23.75% | 19.45% | 10.65% | 19.04% | 28.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.76% | 13.01% | 21.06% | 31.62% | 51.10% |
| Operating Income | -38.09% | -10.49% | -16.99% | -24.86% | -37.22% |
| Income Before Tax | -25.41% | 3.02% | -5.48% | -14.97% | -32.16% |
| Income Tax Expenses | -418.96% | -427.04% | -569.04% | 231.46% | 200.12% |
| Earnings from Continuing Operations | -20.85% | 6.44% | -2.93% | -18.13% | -35.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.85% | 6.44% | -2.93% | -18.13% | -35.38% |
| EBIT | -38.09% | -10.49% | -16.99% | -24.86% | -37.22% |
| EBITDA | -39.26% | -10.52% | -17.12% | -25.33% | -37.20% |
| EPS Basic | 29.70% | 43.93% | 34.10% | 18.59% | -6.77% |
| Normalized Basic EPS | 26.11% | 41.23% | 33.33% | 20.86% | -4.37% |
| EPS Diluted | 29.70% | 43.93% | 34.10% | 18.59% | -6.77% |
| Normalized Diluted EPS | 26.11% | 41.23% | 33.33% | 20.86% | -4.37% |
| Average Basic Shares Outstanding | 67.52% | 63.58% | 59.07% | 47.64% | 30.00% |
| Average Diluted Shares Outstanding | 67.52% | 63.58% | 59.07% | 47.64% | 30.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |